Abstract
Retro-orbital granuloma is a rare and devastating component of granulomatosis with polyangiitis (GPA). Current medical treatment protocols are falling short, and outcomes are poor. The aim of the study was to investigate the frequency, clinical features, and treatment outcomes of retro-orbital granuloma in patients with GPA. This is a retrospective, multi-centre study, which involves GPA cohorts from five different clinics. Data were extracted from patient charts including history, physical examination, radiological–laboratory–histological findings, and treatment protocols. Major clinical outcome measures were changes in the volume of the granuloma on comparative MRI, and visual acuity on repeated ophthalmologic examinations. Among 141 GPA patients, nine (five females and four males) were diagnosed with a retro-orbital granuloma. Median duration of disease was 8 years. Proptosis and diplopia were the dominant presenting symptoms (77 %), followed by orbital pain (55 %). Three out of nine patients had isolated retro-orbital granulomas, without other organ involvement of GPA. Five patients received conventional pulse steroid and pulse cyclophosphamide (CYC) as the first-line remission induction therapy. Four of these patients had progressive disease, and a regression in granuloma size was observed in one patient using this regimen. Two patients were already receiving immunosuppressants when they were diagnosed with retro-orbital granuloma. Six patients had been treated with RTX as the second-line remission induction therapy. None of these patients had progression following RTX therapy. Three patients underwent orbital decompression surgery. The indication for the decision for surgery was either progressive loss of vision or intractable pain. Standard first-line chemotherapy (CYC and steroids) was ineffective against retro-orbital granuloma associated with GPA. RTX could be an alternative in these cases. Surgical intervention may help to decrease the morbidity. Further prospective studies with greater patient numbers are needed to test the clinical efficiency of RTX as a first-line remission induction chemotherapy.
Similar content being viewed by others
References
Pagnoux C et al (2011) Wegener’s granulomatosis strictly and persistently localized to one organ is rare: assessment of 16 patients from the French Vasculitis Study Group database. J Rheumatol 38(3):475–478
Stone JH, Wegener’s G (2003) Granulomatosis Etanercept Trial Research, Limited versus severe Wegener’s granulomatosis: baseline data on patients in the Wegener’s granulomatosis etanercept trial. Arthritis Rheum 48(8):2299–2309
Jayne DR, Rasmussen N (1997) Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Mayo Clin Proc 72(8):737–747
Holle JU et al (2010) Prospective long-term follow-up of patients with localised Wegener’s granulomatosis: does it occur as persistent disease stage? Ann Rheum Dis 69(11):1934–1939
Stone JH et al (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363(3):221–232
Leavitt RY et al (1990) The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum 33(8):1101–1107
Holle JU et al (2013) Orbital masses in granulomatosis with polyangiitis are associated with a refractory course and a high burden of local damage. Rheumatology (Oxford) 52(5):875–882
Haynes BF et al (1977) The ocular manifestations of Wegener’s granulomatosis. Fifteen years experience and review of the literature. Am J Med 63(1):131–141
Talar-Williams C et al (2005) Orbital socket contracture: a complication of inflammatory orbital disease in patients with Wegener’s granulomatosis. Br J Ophthalmol 89(4):493–497
Rothschild PR et al (2013) Ophthalmologic manifestations of systemic necrotizing vasculitides at diagnosis: a retrospective study of 1286 patients and review of the literature. Semin Arthritis Rheum 42(5):507–514
Mukhtyar C et al (2009) EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 68(3):310–317
Specks U et al (2013) Efficacy of remission–induction regimens for ANCA-associated vasculitis. N Engl J Med 369(5):417–427
Joshi L et al (2011) Rituximab in refractory ophthalmic Wegener’s granulomatosis: pR3 titers may predict relapse, but repeat treatment can be effective. Ophthalmology 118(12):2498–2503
Woo TL et al (2001) Australasian orbital and adnexal Wegener’s granulomatosis. Ophthalmology 108(9):1535–1543
Bijlsma WR et al (2011) Orbital mass as manifestation of Wegener’s granulomatosis: an ophthalmologic diagnostic approach. Clin Exp Rheumatol 29(1 Suppl 64):S35–S39
Fauci AS et al (1983) Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 98(1):76–85
Baslund B et al (2012) Treatment of orbital inflammation with rituximab in Wegener’s granulomatosis. Clin Exp Rheumatol 30(1 Suppl 70):S7–S10
Ooka S et al (2009) Treatment of refractory retrobulbar granuloma with rituximab in a patient with ANCA-negative Wegener’s granulomatosis: a case report. Mod Rheumatol 19(1):80–83
Holle JU et al (2012) Rituximab for refractory granulomatosis with polyangiitis (Wegener’s granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis 71(3):327–333
Stone JH et al (2001) Etanercept combined with conventional treatment in Wegener’s granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum 44(5):1149–1154
Bartolucci P et al (2002) Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 41(10):1126–1132
Wegener's Granulomatosis Etanercept Trial (WGET) Research Group (2005) Etanercept plus standard therapy for Wegener’s granulomatosis. N Engl J Med 352(4):351–61
Lamprecht P et al (2002) Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener’s granulomatosis. Rheumatology (Oxford) 41(11):1303–1307
de Menthon M et al (2011) Infliximab or rituximab for refractory Wegener’s granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clin Exp Rheumatol 29(1 Suppl 64):S63–s71
Wygoda A et al (2013) Low dose radiotherapy as an effective treatment in a patient with solitary Wegener’s granulomatosis resistant to systemic treatment—case report. Contemp Oncol (Pozn) 17(1):107–111
Eagleton LE et al (1979) Radiation therapy and mechanical dilation of endobronchial obstruction secondary to Wegener’s granulomatosis. Chest 76(5):609–610
Fechner FP, Faquin WC, Pilch BZ (2002) Wegener’s granulomatosis of the orbit: a clinicopathological study of 15 patients. Laryngoscope 112(11):1945–1950
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bitik, B., Kılıç, L., Küçükşahin, O. et al. Retro-orbital granuloma associated with granulomatosis with polyangiitis: a series of nine cases. Rheumatol Int 35, 1083–1092 (2015). https://doi.org/10.1007/s00296-014-3179-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-014-3179-8